Xenon Pharmaceuticals to Showcase at BofA CNS Therapeutics Conference

The neuroscience-focused company will present its advancements in therapeutics at the virtual event on October 7, 2024.

Xenon Pharmaceuticals is set to participate in the BofA Securities 2024 CNS Therapeutics Virtual Conference.
The company's presentation will be available via live webcast on their website, with a replay option post-event.
Xenon is known for its focus on developing treatments for neurological and psychiatric disorders, including epilepsy and depression.
The presentation will feature Azetukalner, Xenon's lead Kv7 channel opener in late-stage clinical development.
Xenon Pharmaceuticals aims to address high unmet medical needs with its innovative product pipeline.